CORDIS
EU research results

CORDIS

English EN
MicroFluidic based platform for SeMen Analysis

MicroFluidic based platform for SeMen Analysis

Objective

MicroFSMA aims to deliver an assay for semen analysis and isolation of quality sperm for in-vitro fertilization (IVF). An automated, user-friendly, standardized, and efficient method is highly in demand from embryologists/andrologists. MicroFSMA consists three microfluidic chips integrated with a commercial computer program. Microfluidics chips will be designed to replicate in-vivo physical and chemical environment of a female reproductive tract. The thermal and chemical gradient will be generated in microchannels to identify responsive sperm cells.
Additionally, a computer program will facilitate multi-sperm head and flagella tracking for the recorded time-lapse image sequence. Tracking algorithm will connect the positions of sperm cells in recorded successive images. The continuous wavelet analysis (CWT) /harmonic analysis of the flagellar wave and head trajectory will assist to identify the responsive sperm cell towards the chemical/physical cues. We are convinced that the correlation of sperm kinematics with harmonics/wavelet analysis will reveal potential parameters for male infertility screening.
The successful employment of MicroFSMA in an industrial atmosphere will improve the experienced researcher (ER) knowledge of industrial R&D and market strategy. These unconventional skills will ensure the complete exploitation of MicroFSMA results by starting the small-medium enterprise(SME)/academic joint research schemes.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

CHERRY BIOTECH

Address

6 Rue Gurvand
35000 Rennes

France

Activity type

Other

EU Contribution

€ 196 707,84

Project information

Grant agreement ID: 842299

Status

Grant agreement signed

  • Start date

    1 July 2019

  • End date

    30 June 2021

Funded under:

H2020-EU.1.3.2.

  • Overall budget:

    € 196 707,84

  • EU contribution

    € 196 707,84

Coordinated by:

CHERRY BIOTECH

France